Fabrication and evaluation of tumor-targeted positive MRI contrast agent based on ultrasmall MnO nanoparticles

Haitao Huang, Tao Yue, Ke Xu, Jafar Golzarian, Jiahui Yu, Jin Huang

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Gd(III) chelate is currently used as positive magnetic resonance imaging (MRI) contrast agent in clinical diagnosis, but generally induces the risk of nephrogenic systemic fibrosis (NSF) due to the dissociated Gd3+ from Gd(III) chelates. To develop a novel positive MRI contrast agent with low toxicity and high sensitivity, ultrasmall MnO nanoparticles were PEGylated via catechol-Mn chelation and conjugated with cRGD as active targeting function to tumor. Particularly, the MnO nanoparticles with a size of ca. 5nm were modified by α,β-poly(aspartic acid)-based graft polymer containing PEG and DOPA moieties and, meanwhile, conjugated with cRGD to produce the contrast agent with a size of ca. 100nm and a longitudinal relaxivity (r1) of 10.2mM-1S-1. Such nanoscaled contrast agent integrated passive- and active-targeting function to tumor, and its efficient accumulation behavior in tumor was verified by in vivo distribution study. At the same time, the PEG moiety played a role of hydrophilic coating to improve the biocompatibility and stability under storing and physiological conditions, and especially might guarantee enough circulation time in blood. Moreover, in vivo MRI revealed a good and long-term effect of enhancing MRI signal for as-fabricated contrast agent while cell viability assay proved its acceptable cytotoxicity for MRI application. On the whole, the as-fabricated PEGylated and cRGD-functionalized contrast agent based on ultrasmall MnO nanoparticles showed a great potential to the T1-weighted MRI diagnosis of tumor.

Original languageEnglish (US)
Pages (from-to)148-154
Number of pages7
JournalColloids and Surfaces B: Biointerfaces
Volume131
DOIs
StatePublished - Apr 29 2015

Bibliographical note

Funding Information:
The research work was supported by the International Science & Technology Cooperation Program of China, Ministry of Science and Technology of China ( 2014DFG52500 ), Shanghai Municipality Commission for Special Project of Nanometer Science and Technology ( 11nm0506000 ), the National Natural Science Foundation of China ( 81171333 ), and the EU-FP 7 project ( MARINA 263215 ).

Keywords

  • CRGD
  • Longitudinal relaxivity
  • Magnetic resonance imaging
  • Positive contrast agent
  • Ultrasmall MnO nanoparticles

Fingerprint Dive into the research topics of 'Fabrication and evaluation of tumor-targeted positive MRI contrast agent based on ultrasmall MnO nanoparticles'. Together they form a unique fingerprint.

Cite this